Calculators and Tools for COPD

GOLD staging uses post-bronchodilator FEV₁/FVC <0.70 to confirm airflow obstruction, then grades by FEV₁% predicted: GOLD 1 (mild) ≥80%; GOLD 2 (moderate) 50–79%; GOLD 3 (severe) 30–49%; GOLD 4 (very severe) <30%. Combined GOLD assessment (ABE groups) also uses mMRC dyspnea score (≥2 = more symptoms) and exacerbation history (≥2/year or ≥1 requiring hospitalization = high risk). Treatment escalation: GOLD A = SABA PRN; B = LAMA or LABA; E (formerly C/D) = LAMA + LABA ± ICS based on eosinophil count and exacerbation history.

BODE (BMI, Obstruction by FEV₁, Dyspnea by mMRC, Exercise by 6-minute walk distance) scores 0–10 and predicts all-cause and respiratory mortality in COPD. BODE 0–2: 4-year survival ~80%; BODE 3–4: ~67%; BODE 5–6: ~57%; BODE 7–10: ~18%. A BODE score >5 is a risk factor for acute respiratory failure and may indicate eligibility for lung volume reduction surgery evaluation. BODE >7 suggests median survival <4 years — lung transplant referral should be considered. Pulmonary rehabilitation improves 6MWD and mMRC scores, favorably shifting BODE score.

Pack-years = (cigarettes per day ÷ 20) × years smoked. GOLD criteria for COPD diagnosis includes smoking history ≥10 pack-years combined with symptoms and spirometry confirmation. USPSTF (2021) recommends annual low-dose CT lung cancer screening for adults aged 50–80 with ≥20 pack-years who currently smoke or quit within the past 15 years. For COPD risk, even 10 pack-years causes measurable airflow limitation in susceptible individuals. Smoking cessation remains the single most effective intervention to slow COPD progression.

Long-term oxygen therapy (LTOT) is indicated when resting PaO₂ ≤55 mmHg (SpO₂ ≤88%) or PaO₂ 56–59 mmHg with polycythemia (Hct >55%) or cor pulmonale. Target SpO₂: 88–92% in COPD with hypercapnia risk (not 94–98% as in non-COPD) to avoid hypercapnic respiratory failure. FiO₂ delivery: nasal cannula at 1–2 L/min ≈ 25–29% FiO₂; maximum nasal cannula is 6 L/min ≈ 45%. Venturi masks provide the most precise FiO₂. In acute exacerbations, titrate oxygen to SpO₂ 88–92% — not to patient comfort.

ABG is essential in: acute exacerbations with SpO₂ <92%, suspected hypercapnia, before initiating NIV, and when oximetry is unreliable (carboxyhemoglobin in smokers). COPD hypercapnia interpretation: compensated respiratory acidosis = elevated PaCO₂ with near-normal pH (chronic); acute-on-chronic = abrupt pH fall <7.35 with elevated PaCO₂. NIV indication in acute exacerbation: pH <7.35 + PaCO₂ >45 mmHg despite controlled oxygen. A-a gradient distinguishes hypoventilation (normal gradient) from V/Q mismatch or shunt (elevated gradient) in COPD exacerbations.

mMRC ≥2 (stops after 100m on the level due to breathlessness, or unable to walk at own pace) is the key threshold for pulmonary rehabilitation referral per NICE and GOLD guidelines. Pulmonary rehab reduces dyspnea, improves exercise tolerance and quality of life, and reduces hospitalization and mortality after acute exacerbation. Benefits are greatest when started within 4 weeks of an acute exacerbation hospitalization (high-quality evidence). Exercise training, education, and self-management support are core components.